Tackling COVID-19 with neutralizing monoclonal antibodies.
Tackling COVID-19 with neutralizing monoclonal antibodies.
复制标题
DOI：
10.1016/j.cell.2021.05.005
复制
发表时间：
2021-06-10
期刊：
影响因子：
64.5
通讯作者：
Veesler D
中科院分区：
文献类型：
--
作者：
Corti D;Purcell LA;Snell G;Veesler D
单克隆抗体（mab）已经彻底改变了几种人类疾病的治疗，包括癌症、自身免疫和炎症性疾病，并代表了传染病治疗的新前沿。在过去的20年里，创新的方法已经允许从恢复期受试者、人源化小鼠或体外组装的文库中快速分离单克隆抗体，并证明单克隆抗体可以有效地对抗新出现的病原体。在过去的一年里，开发出了前所未有的大量单克隆抗体来对抗2019冠状病毒病（COVID-19）。从这次大流行中吸取的经验教训将为开发更多基于单克隆抗体的其他传染病治疗方法铺平道路。在这里，我们概述了sars - cov -2中和单克隆抗体，包括它们的起源、特异性、结构、抗病毒和免疫作用机制，以及对循环变体的耐药性，以及已批准或晚期单克隆抗体治疗的临床试验概况。为开发或鉴定治疗COVID-19患者的药物作出了巨大努力。单克隆抗体是少数几种在临床中显示出疗效的药物之一。
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human diseases, including cancer and autoimmunity and inflammatory conditions, and represent a new frontier for the treatment of infectious diseases. In the last 20 years, innovative methods have allowed the rapid isolation of mAbs from convalescent subjects, humanized mice, or libraries assembled in vitro and have proven that mAbs can be effective countermeasures against emerging pathogens. During the past year, an unprecedentedly large number of mAbs have been developed to fight coronavirus disease 2019 (COVID-19). Lessons learned from this pandemic will pave the way for the development of more mAb-based therapeutics for other infectious diseases. Here, we provide an overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics. Intense efforts have been made to develop or identify drugs to treat people with COVID-19. Monoclonal antibodies are one of the few types of drugs that have shown efficacy in the clinic.
登录
查看更多内容
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
DOI：
10.4049/jimmunol.2000583
发表时间：
2020-08-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Alsoussi WB;Turner JS;Case JB;Zhao H;Schmitz AJ;Zhou JQ;Chen RE;Lei T;Rizk AA;McIntire KM;Winkler ES;Fox JM;Kafai NM;Thackray LB;Hassan AO;Amanat F;Krammer F;Watson CT;Kleinstein SH;Fremont DH;Diamond MS;Ellebedy AH
通讯作者：
Ellebedy AH
REGN-COV2抗体预防和治疗恒河猕猴和仓鼠中的SARS-COV-2感染。
DOI：
10.1126/science.abe2402
发表时间：
2020-11-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者：
Kyratsous CA
影响因子：
64.8
作者：
通讯作者：
--